News & Updates
The 11th FDA-Approved Therapy Treatment from Abramson Cancer Center
Sunday, September 20, 2020
Research led by Adam. D. Cohen from Penn Medicine’s Abramson Cancer Center produced a new immunotherapy called Belantamab Mafodotin (Blenrep). The US Food & Drug Administration (FDA) established approval for this treatment on August 5, 2020 which will give adult patients who have relapsed or have refractory multiple myeloma another remedy. This marks the 11th FDA-approved therapy from a member of the Abramson Cancer Center.
Due to the lack of treatment options for multiple myeloma patients, this new form has the potential to make a huge impact on patients’ lives. Blenrep works by targeting BCMA which is an original mark on the surface of myeloma cells. This must be a last resort for patients as they are required to have at least completed 4 prior lines of therapy including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Philly Fights Cancer is extremely proud to continue to fund vital research and clinical trials that make advances like these from Abramson Cancer Center possible. For more information on this new treatment visit the FDA or watch Penn’s Official Announcement.
Share this post
Research led by Adam. D. Cohen from Penn Medicine’s Abramson Cancer Center produced a new immunotherapy called Belantamab Mafodotin (Blenrep). The US Food & Drug Administration (FDA) established approval for this treatment on August 5, 2020 which will give adult patients who have relapsed or have refractory multiple myeloma another remedy. This marks the 11th FDA-approved therapy from a member of the Abramson Cancer Center.
Due to the lack of treatment options for multiple myeloma patients, this new form has the potential to make a huge impact on patients’ lives. Blenrep works by targeting BCMA which is an original mark on the surface of myeloma cells. This must be a last resort for patients as they are required to have at least completed 4 prior lines of therapy including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Philly Fights Cancer is extremely proud to continue to fund vital research and clinical trials that make advances like these from Abramson Cancer Center possible. For more information on this new treatment visit the FDA or watch Penn’s Official Announcement.